SIRT6 and prostate carcinoma: Liu et al. demonstrated that siRNA-mediated inhibition of SIRT6 induces cell cycle arrest at the sub-G1 phase, decreases Bcl-2 expression, induces apoptosis, increases DNA damage, and enhances chemotherapeutic sensitivity of PC3 and DU145 prostate cancer cells [102].